Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | BHMT | Q93088 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.34 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL286783 | 1.00 | TSHR (0.43) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL12268201 | 1.00 | TSHR (0.43) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL28861626 | 0.98 | TSHR (0.41) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL265822 | 0.90 | TSHR (0.50) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL30884920 | 0.85 | ALDH1A1 (0.35) | TSHRHSD17B10ALDH1A1KDM4EBHMT | |
| Alcohol SCHEMBL28286197 | 0.83 | TSHR (0.43) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL316476 | 0.83 | SLC22A6 (0.38) | HSD17B10ALDH1A1KDM4EBHMTSLC22A6 | |
| SCHEMBL258152 | 0.82 | SLC22A6 (0.50) | TSHRALDH1A1BHMTSLC22A6MAPT | |
| SCHEMBL12158758 | 0.81 | MGAM (0.50) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL14532417 | 0.81 | MGAM (0.50) | TSHRHSD17B10MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118223049-B | Micro-reaction process and system for electrolytically synthesizing musk ketone precursor by using circulating flow | 宏济堂制药(商河)有限公司 | 2024-09-17 | — | — | CN | claimed |
| CN-118223049-A | Micro-reaction process and system for electrolytically synthesizing musk ketone precursor by using circulating flow | 宏济堂制药(商河)有限公司 | 2024-06-21 | — | — | CN | claimed |
| CN-108383723-B | Preparation method of beta-methyl glutarate monomethyl ester with high purity and high yield | 淄博职业学院 | 2021-03-23 | — | — | CN | claimed |
| CN-107337592-B | Method for synthesizing muscone by using beta-methyl glutarate monomethyl ester | 辽宁科技学院 | 2020-11-13 | — | — | CN | claimed |
| CN-108383723-A | The preparation method of high-purity, high yield Beta-methyl monomethyl glutarate | 淄博职业学院 | 2018-08-10 | — | — | CN | claimed |
| CN-108107125-A | A kind of content assaying method of Beta-methyl monomethyl glutarate | 山东宏济堂制药集团股份有限公司 | 2018-06-01 | — | — | CN | claimed |
| CN-107337592-A | Utilize the method for β methylglutaric acid mono-methyl musk ambrette ketone | 辽宁科技学院 | 2017-11-10 | — | — | CN | claimed |
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20250145611-A1 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4543439-A2 | NRF2 PROTEIN DEGRADERS | Ganymede Oncology, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119804716-A | Central control detection method for electrolytic reaction of synthetic musk ketone precursor | 宏济堂制药(商河)有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119730847-A | NRF2 protein degradation agent | 盖尼米德肿瘤学股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20240360149-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2024-10-31 | — | — | US | disclosed |
| EP-0713420-A1 | CARTRIDGE FILTER WITH INSOLUBLE ENZYME PARTICULATES CONTAINED THEREON | MINNESOTA MINING & MFG (US) | 1996-05-29 | — | — | EP | disclosed |
| US-5478466-A | Multilayer comprising porous fibrous layer and immobilized enzyme catalyst powder top layer | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-12-26 | — | — | US | disclosed |
| WO-1995005233-A1 | CARTRIDGE FILTER WITH INSOLUBLE ENZYME PARTICULATES CONTAINED THEREON | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-02-23 | — | — | WO | disclosed |
| US-5262313-A | Reaction of carrageen with esterase and hardening drops | ANDCARE, INC. (US) | 1993-11-16 | — | — | US | disclosed |
| US-5144021-A | Reticulated cellulose and methods and microorganisms for the production thereof | WEYERHAEUSER COMPANY (US) | 1992-09-01 | — | — | US | disclosed |
| US-5079162-A | High purity Acetobacter, cellulose with high tensile strength | WEYERHAEUSER COMPANY (US) | 1992-01-07 | — | — | US | disclosed |
| US-4863565-A | Sheeted products formed from reticulated microbial cellulose | WEYERHAEUSER COMPANY (US) | 1989-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | TSHR 2615/4885HSD17B10 346/4885MGAM 3637/4885 |
| US-20250145611-A1 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | TSHR 2255/4885HSD17B10 2063/4885MGAM 3115/4885 |
| US-20240360149-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | TSHR 4169/4885HSD17B10 2015/4885MGAM 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.